Isfort, Susanne http://orcid.org/0000-0002-2855-561X
Manz, Kirsi
Teichmann, Lino L.
Crysandt, Martina
Burchert, Andreas
Hochhaus, Andreas
Saussele, Susanne
Kiani, Alexander
Göthert, Joachim R.
Illmer, Thomas
Schafhausen, Philippe
Al-Ali, Haifa Kathrin
Stegelmann, Frank
Hänel, Mathias
Pfeiffer, Tim
Giagounidis, Aristoteles
Franke, Georg-Nikolaus
Koschmieder, Steffen
Fabarius, Alice
Ernst, Thomas
Warnken-Uhlich, Mareille
Wolber, Uta
Kohn, Denise
Pfirrmann, Markus
Wolf, Dominik
Brümmendorf, Tim H.
,
Funding for this research was provided by:
Pfizer Pharmaceuticals
RWTH Aachen University
Article History
Received: 30 March 2023
Accepted: 29 July 2023
First Online: 18 August 2023
Declarations
:
: The study was approved by institutional review boards and independent ethics committees at each center (leading ethics committee: ethics committee at the medical faculty of the University of Bonn) and conducted in accordance with all local legal and regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Pts, Guidelines for Good Clinical Practice and the Declaration of Helsinki. All pts provided written informed consent at study inclusion.
: SI reports advisory board honoraria from GSK, Pfizer, Incyte, and Novartis, honoraria from Novartis, BMS, Pfizer, Incyte, and AOP Orphan; and other financial support (e.g., travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal, and AOP Orphan. LT reports advisory activity for Pfizer. MC reports honoraria from Pfizer, Incyte, Astra Zeneca, and Novartis. AB reports research funding from AOP health, honoraria from AOP Orphan, and membership on an entity´s board of directors or advisory committees from Gilead, Pfizer, and Incyte. AH reports research support from Novartis, Pfizer, BMS, and Incyte. SS reports research funding from Novartis, BMS, and Incyte and honoraria from Novartis, BMS, Incyte, Pfizer, and Roche. AK reports honoraria, advisory role, and travel support from Pfizer. JRG reports honoraria, advisory board membership, and consultancy roles for Pfizer. PS reports consulting/advisory role/honoraria/travel and accommodation support from Alexion, AOP Orphan, Blueprint Medicines, BMS/Celgene, Merck Serono, MSD, Novartis, Pfizer, Roche, and Sobi. FS reports honoraria from and consultancy for Abbvie, AOP Pharma, BMS/Celgene, Incyte, Novartis, and Pfizer. MH reports advisory board honoraria from Novartis and Pfizer and honoraria from Novartis. GF reports honoraria/advisory board honoraria from Novartis, Pfizer, and MSD and travel support from Gilead and Takeda. SK reports funding from Novartis and Bristol-Myers Squibb; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, and BMS; patent for BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Pfizer, Incyte, and Ariad; and other financial support (e.g., travel support) from Novartis, BMS, Incyte, Ariad, and Pfizer. DW reports advisory board honoraria, honoraria, and research support from Pfizer, BMS, Incyte, and Novartis. THB reports consultancy from Janssen, Merck, Novartis, and Pfizer, research funding from Novartis and Pfizer, honoraria from Pfizer and Novartis, and other expenses (travel, accommodation, expenses) from Janssen, Merck, Novartis, and Pfizer. KM, TI, AF, TE, HKA, AG, TP, MWU, UW, DK, and MP report no conflicts of interest.